Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30937481 | 1.00 | ERN1 (0.49) | ERN1CA12CA1CA2CA9 | |
| SCHEMBL6188476 | 0.91 | CA12 (0.46) | ERN1CA12CA1CA2CA9 | |
| SCHEMBL29935810 | 0.84 | ERN1 (0.49) | ERN1CA12CA1CA2CA9 | |
| SCHEMBL1052852 | 0.84 | ERN1 (0.49) | ERN1CA12CA1CA2CA9 | |
| SCHEMBL25403169 | 0.82 | CA12 (0.46) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL16096641 | 0.80 | ALDH1A1 (0.38) | ERN1CA12CA1CA2CA9 | |
| SCHEMBL26119644 | 0.79 | ALDH1A3 (0.39) | ERN1CA12CA1CA2CA9 | |
| SCHEMBL17895679 | 0.79 | CA12 (0.53) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL21484579 | 0.78 | CYP3A4 (0.47) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL26844605 | 0.78 | SLC22A12 (0.51) | ERN1ALDH1A1TSHRTDP1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905272-B1 | 3-(2-(4-methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine as an anti-cancer compound | King Faisal University (SA) | 2024-02-20 | — | — | US | claimed |
| EP-1611102-A4 | USING ALKYLMETAL REAGENTS FOR DIRECTED METALATION OF AZAAROMATICS | FMC CORP (US) | 2009-04-01 | — | — | EP | claimed |
| US-7129360-B2 | Using alkylmetal reagents for directed metalation of azaaromatics | FMC CORPORATION (US) | 2006-10-31 | — | — | US | claimed |
| EP-1611102-A2 | USING ALKYLMETAL REAGENTS FOR DIRECTED METALATION OF AZAAROMATICS | FMC CORPORATION (US) | 2006-01-04 | — | — | EP | claimed |
| US-20040230055-A1 | Using alkylmetal reagents for directed metalation of azaaromatics | FMC CORPORATION | 2004-11-18 | — | — | US | claimed |
| WO-2004092125-A2 | USING ALKYLMETAL REAGENTS FOR DIRECTED METALATION OF AZAAROMATICS | FMC CORPORATION (US) | 2004-10-28 | — | — | WO | claimed |
| EP-4629988-A1 | DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER AND INFECTIONS | Centre National de la Recherche Scientifique (FR) | 2025-10-15 | — | — | EP | disclosed |
| US-20250084052-A1 | 3-(2-(4-METHOXYPYRIDIN-3-YL)-4,5-DIPHENYL-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPROPAN-1-AMINE AS AN ANTI-CANCER COMPOUND | King Faisal University (SA) | 2025-03-13 | — | — | US | disclosed |
| CN-118359638-A | Compound serving as RET kinase inhibitor and preparation method and application thereof | 苏州朗睿生物医药有限公司 | 2024-07-19 | — | — | CN | disclosed |
| WO-2024121072-A1 | DERIVATIVES OF INDOLE FOR THE TREATMENT OF CANCER AND INFECTIONS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-06-13 | — | — | WO | disclosed |
| US-11905272-B1 | 3-(2-(4-methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine as an anti-cancer compound | King Faisal University (SA) | 2024-02-20 | — | — | US | disclosed |
| CN-112041311-B | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-114502556-B | Biphenyl fluoro double bond derivative, preparation method thereof and application thereof in pharmacy | 上海和誉生物医药科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-0659737-B1 | Catecholamine surrogates useful as beta 3 agonists | BRISTOL MYERS SQUIBB CO (US) | 2003-03-26 | — | — | EP | disclosed |
| EP-0714395-B1 | VASOCONSTRICTIVE SUBSTITUTED DIHYDROPYRANOPYRIDINES | JANSSEN PHARMACEUTICA NV (BE) | 1999-03-31 | — | — | EP | disclosed |
| US-5776983-A | ANTIDIABETIC AGENTS, OBESITY, GASTROINTESTINAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-07 | — | — | US | disclosed |
| US-5691344-A | Vasoconstrictive substituted dihydropyranopyridines | JANSSEN PHARMACEUTICA, N.V. (BE) | 1997-11-25 | — | — | US | disclosed |
| EP-0714395-A1 | VASOCONSTRICTIVE SUBSTITUTED DIHYDROPYRANOPYRIDINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-06-05 | — | — | EP | disclosed |
| EP-0659737-A2 | Catecholamine surrogates useful as B3 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-06-28 | — | — | EP | disclosed |
| WO-1995005381-A1 | VASOCONSTRICTIVE SUBSTITUTED DIHYDROPYRANOPYRIDINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905272-B1 | 3-(2-(4-methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine as an anti-cancer compound | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, API5, MCL1 | ERN1 986/4885CA12 4394/4885CA1 4677/4885 |
| US-20250084052-A1 | 3-(2-(4-METHOXYPYRIDIN-3-YL)-4,5-DIPHENYL-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPROPAN-1-AMINE AS AN ANTI-CANCER COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, API5, MCL1 | ERN1 986/4885CA12 4394/4885CA1 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.